The Securities and Exchange Commission has announced that it has resolved civil FCPA charges against the French drug company, Sanofi, and its Kazakh and Middle Eastern subsidiaries. The company will pay $25 million to settle allegations that it participated in bribery schemes to secure government tenders and increase prescriptions.
September 4, 2018
Pharmaceutical giant charged with bribery
Related by Topic
New Post
DOJ issues declination with disgorgement letter to Boston Consulting Group for possible FCPA offenses
August 29, 2024
News Alert
New Post
Former oil and gas trader pleads guilty to additional FCPA charges
August 23, 2024
News Alert
Smartmatic executives indicted for money laundering and FCPA violations
August 12, 2024
News Alert